Please use this identifier to cite or link to this item:
Title: The Effect Of Drug Dx23 Towards Enhancing Neutrophil Function And Regulating Immune Response
Authors: Aiko, Keita
Keywords: DX23
novel drug target
immune response
Issue Date: 18-Jan-2024
Publisher: Indonesia International Institute for Life Sciences
Series/Report no.: EP BM-005;EP24-047
Abstract: Neutrophils are the main cells that play a significant role in the innate immune system. Upon a pathogenic invasion, these cells are recruited to the site of infection and perform many different functions. Targeting the neutrophils for therapeutic interventions has been a great challenge due to the complexity of their signaling pathway and mechanisms. Therefore, the search for drug candidates that enhance neutrophil function remains questionable. DX23 is a type of CFTR potentiator originally used to treat patients with cystic fibrosis However, this research would like to test the potential of DX23 as one of the drug candidates tested for enhancing neutrophil activity. Moreover, the experiment utilizes spectrophotometry, flow cytometry, and luminometer to elucidate the molecular mechanisms underlying the responses of neutrophils and identify targets for treating neutrophil-associated diseases. In this study, DX23 was found to enhance superoxide anion production, reactive oxygen species generation, and elastase release in human neutrophils. Additionally, DX23 is able to promote the formation of NETs in order to initiate immune defense. Further study also shows that DX23 promotes the generation of primary and secondary granules during degradation in CD marker detection.
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
Abstract.pdfAbstract56.16 kBAdobe PDFView/Open
Chapter 1.pdfChapter 167.38 kBAdobe PDFView/Open
Cover.pdfCover111.19 kBAdobe PDFView/Open
EP2024_BM_Keita Aiko.pdf
  Restricted Access
Full Text1.32 MBAdobe PDFView/Open Request a copy
References.pdfReferences150.75 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.